-transparent.png){kind=logo}
Twenty-five inpatients with acute exacerbations of schizophrenia (by Research Diagnostic Criteria) or schizoaffective disorder underwent a prospective haloperidol dosing procedure and were assigned fixed doses chosen to yield a distribution of haloperidol plasma levels above and below a hypothesized upper therapeutic limit of 18 ng/ml. Changes in Brief Psychiatric Rating Scale scores after 1 week of treatment were negatively correlated with haloperidol plasma levels, and the statistically optimum cutoff point fell near the predicted 18 ng/ml. Plasma level/response relationships over the subsequent 3 weeks were weaker but patients with higher plasma levels had consistently less improvement.
W Coryell, and
M Kelly, and
P J Perry, and
D D Miller
October 1982,
Psychopharmacology bulletin,
W Coryell, and
M Kelly, and
P J Perry, and
D D Miller
January 1983,
Psychopharmacology,
W Coryell, and
M Kelly, and
P J Perry, and
D D Miller
January 1984,
European archives of psychiatry and neurological sciences,
W Coryell, and
M Kelly, and
P J Perry, and
D D Miller
October 1995,
Archives of general psychiatry,
W Coryell, and
M Kelly, and
P J Perry, and
D D Miller
August 1982,
The American journal of psychiatry,
W Coryell, and
M Kelly, and
P J Perry, and
D D Miller
August 1989,
Biological psychiatry,
W Coryell, and
M Kelly, and
P J Perry, and
D D Miller
March 1994,
Progress in neuro-psychopharmacology & biological psychiatry,
W Coryell, and
M Kelly, and
P J Perry, and
D D Miller
October 1998,
Psychiatry research,
W Coryell, and
M Kelly, and
P J Perry, and
D D Miller
September 1992,
Pharmacopsychiatry,
W Coryell, and
M Kelly, and
P J Perry, and
D D Miller
December 1987,
Archives of general psychiatry,
